• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三元固体分散体:制备、表征、药物释放机制及物理稳定性综述

Ternary Solid Dispersions: A Review of the Preparation, Characterization, Mechanism of Drug Release, and Physical Stability.

作者信息

Budiman Arif, Lailasari Eli, Nurani Neng Vera, Yunita Ellen Nathania, Anastasya Gracia, Aulia Rizqa Nurul, Lestari Ira Novianty, Subra Laila, Aulifa Diah Lia

机构信息

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia.

Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia.

出版信息

Pharmaceutics. 2023 Aug 10;15(8):2116. doi: 10.3390/pharmaceutics15082116.

DOI:10.3390/pharmaceutics15082116
PMID:37631330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10459848/
Abstract

The prevalence of active pharmaceutical ingredients (APIs) with low water solubility has experienced a significant increase in recent years. These APIs present challenges in formulation, particularly for oral dosage forms, despite their considerable therapeutic potential. Therefore, the improvement of solubility has become a major concern for pharmaceutical enterprises to increase the bioavailability of APIs. A promising formulation approach that can effectively improve the dissolution profile and the bioavailability of poorly water-soluble drugs is the utilization of amorphous systems. Numerous formulation methods have been developed to enhance poorly water-soluble drugs through amorphization systems, including co-amorphous formulations, amorphous solid dispersions (ASDs), and the use of mesoporous silica as a carrier. Furthermore, the successful enhancement of certain drugs with poor aqueous solubility through amorphization has led to their incorporation into various commercially available preparations, such as ASDs, where the crystalline structure of APIs is transformed into an amorphous state within a hydrophilic matrix. A novel approach, known as ternary solid dispersions (TSDs), has emerged to address the solubility and bioavailability challenges associated with amorphous drugs. Meanwhile, the introduction of a third component in the ASD and co-amorphous systems has demonstrated the potential to improve performance in terms of solubility, physical stability, and processability. This comprehensive review discusses the preparation and characterization of poorly water-soluble drugs in ternary solid dispersions and their mechanisms of drug release and physical stability.

摘要

近年来,低水溶性活性药物成分(API)的比例显著增加。尽管这些API具有相当大的治疗潜力,但它们在制剂方面存在挑战,尤其是对于口服剂型。因此,提高溶解度已成为制药企业提高API生物利用度的主要关注点。一种有前景的制剂方法是利用无定形体系,它可以有效改善难溶性药物的溶出曲线和生物利用度。已经开发了许多通过无定形化系统增强难溶性药物的制剂方法,包括共无定形制剂、无定形固体分散体(ASD)以及使用介孔二氧化硅作为载体。此外,通过无定形化成功提高了某些水溶性差的药物的性能,使其被纳入各种市售制剂中,如ASD,其中API的晶体结构在亲水性基质中转变为无定形状态。一种称为三元固体分散体(TSD)的新方法已经出现,以应对与无定形药物相关的溶解度和生物利用度挑战。同时,在ASD和共无定形系统中引入第三种成分已显示出在溶解度、物理稳定性和可加工性方面改善性能的潜力。这篇综述讨论了三元固体分散体中难溶性药物的制备、表征及其药物释放和物理稳定性机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/33a5cb046464/pharmaceutics-15-02116-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/ab7c9d6f8a25/pharmaceutics-15-02116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/cbb99e7d50fd/pharmaceutics-15-02116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/23cdf5cf6e53/pharmaceutics-15-02116-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/ece1ff5ee553/pharmaceutics-15-02116-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/52534893c867/pharmaceutics-15-02116-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/6eefd3eefa41/pharmaceutics-15-02116-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/1d2b0a61d1ac/pharmaceutics-15-02116-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/33a5cb046464/pharmaceutics-15-02116-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/ab7c9d6f8a25/pharmaceutics-15-02116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/cbb99e7d50fd/pharmaceutics-15-02116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/23cdf5cf6e53/pharmaceutics-15-02116-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/ece1ff5ee553/pharmaceutics-15-02116-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/52534893c867/pharmaceutics-15-02116-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/6eefd3eefa41/pharmaceutics-15-02116-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/1d2b0a61d1ac/pharmaceutics-15-02116-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f04/10459848/33a5cb046464/pharmaceutics-15-02116-g008.jpg

相似文献

1
Ternary Solid Dispersions: A Review of the Preparation, Characterization, Mechanism of Drug Release, and Physical Stability.三元固体分散体:制备、表征、药物释放机制及物理稳定性综述
Pharmaceutics. 2023 Aug 10;15(8):2116. doi: 10.3390/pharmaceutics15082116.
2
Ternary solid dispersions: classification and formulation considerations.三元固体分散体:分类和制剂考虑因素。
Drug Dev Ind Pharm. 2021 Jul;47(7):1011-1028. doi: 10.1080/03639045.2021.1908342. Epub 2021 Aug 17.
3
Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.喷雾干燥三元无定形固体分散体的固态特性和溶出特性研究:多组分无定形系统设计和开发的合理步骤。
Mol Pharm. 2018 Sep 4;15(9):3796-3812. doi: 10.1021/acs.molpharmaceut.8b00306. Epub 2018 Jul 30.
4
Recent Technologies for Amorphization of Poorly Water-Soluble Drugs.难溶性药物非晶化的最新技术
Pharmaceutics. 2021 Aug 23;13(8):1318. doi: 10.3390/pharmaceutics13081318.
5
Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review.静电纺丝技术制备的难溶性药物无定形固体分散体:综述
J Control Release. 2018 Dec 28;292:91-110. doi: 10.1016/j.jconrel.2018.08.016. Epub 2018 Aug 14.
6
Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.聚合物无定形固体分散体:生物药剂学分类系统II类药物的非晶化、结晶、稳定化、固态表征及水相增溶综述
J Pharm Sci. 2016 Sep;105(9):2527-2544. doi: 10.1016/j.xphs.2015.10.008. Epub 2016 Jan 23.
7
Ball milling and hot-melt extrusion of indomethacin-l-arginine-vinylpyrrolidone-vinyl acetate copolymer: Solid-state properties and dissolution performance.吲哚美辛 - L - 精氨酸 - 乙烯基吡咯烷酮 - 醋酸乙烯酯共聚物的球磨法与热熔挤出法:固态性质与溶解性能
Int J Pharm. 2022 Feb 5;613:121424. doi: 10.1016/j.ijpharm.2021.121424. Epub 2021 Dec 28.
8
Spray-Dried Amorphous Solid Dispersions of Atorvastatin Calcium for Improved Supersaturation and Oral Bioavailability.阿托伐他汀钙喷雾干燥无定形固体分散体用于改善过饱和度和口服生物利用度。
Pharmaceutics. 2019 Sep 6;11(9):461. doi: 10.3390/pharmaceutics11090461.
9
Evaluation of Suitable Polymeric Matrix/Carriers during Loading of Poorly Water Soluble Drugs onto Mesoporous Silica: Physical Stability and In Vitro Supersaturation.难溶性药物负载于介孔二氧化硅过程中合适聚合物基质/载体的评估:物理稳定性和体外过饱和现象
Polymers (Basel). 2024 Mar 13;16(6):802. doi: 10.3390/polym16060802.
10
Hydrogenated phospholipid, a promising excipient in amorphous solid dispersions of fenofibrate for oral delivery: Preparation and in-vitro biopharmaceutical characterization.氢化磷脂,一种在非晶态固体分散体中的有前途的赋形剂,用于口服递送非诺贝特:制备和体外生物药剂学特性。
Int J Pharm. 2023 Sep 25;644:123294. doi: 10.1016/j.ijpharm.2023.123294. Epub 2023 Aug 6.

引用本文的文献

1
Kinetics of Phase Transitions in Amorphous Carbamazepine: From Sub- Structural Relaxation to High-Temperature Decomposition.非晶态卡马西平的相变动力学:从亚结构弛豫到高温分解
Int J Mol Sci. 2025 Jun 26;26(13):6136. doi: 10.3390/ijms26136136.
2
Ternary Solid Dispersions as an Alternative Approach to Enhance Pharmacological Activity.三元固体分散体作为增强药理活性的替代方法。
Drug Des Devel Ther. 2025 Jul 3;19:5663-5684. doi: 10.2147/DDDT.S533359. eCollection 2025.
3
Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability.

本文引用的文献

1
Preparation of a ternary amorphous solid dispersion using hot-melt extrusion for obtaining a stable colloidal dispersion of amorphous probucol nanoparticles.采用热熔挤出法制备三元无定形固体分散体以获得无定形普罗布考纳米粒子的稳定胶体分散体。
Int J Pharm. 2023 Jun 10;640:122959. doi: 10.1016/j.ijpharm.2023.122959. Epub 2023 Apr 20.
2
Development of a multiparticulate drug delivery system for in situ amorphisation.用于原位非晶化的多颗粒药物传递系统的开发。
Eur J Pharm Biopharm. 2022 Nov;180:170-180. doi: 10.1016/j.ejpb.2022.09.021. Epub 2022 Oct 1.
3
Design of Ternary Amorphous Solid Dispersions for Enhanced Dissolution of Drug Combinations.
制备、表征和评价具有增强口服生物利用度的尼达尼布无定形固体分散体。
AAPS PharmSciTech. 2024 Aug 13;25(6):183. doi: 10.1208/s12249-024-02902-x.
4
Mechanochemical Approach to Obtaining a Multicomponent Fisetin Delivery System Improving Its Solubility and Biological Activity.机械化学法制备多组分非瑟酮给药系统以提高其溶解度和生物活性。
Int J Mol Sci. 2024 Mar 25;25(7):3648. doi: 10.3390/ijms25073648.
三元无定形固体分散体的设计增强药物组合的溶解。
Mol Pharm. 2022 Aug 1;19(8):2950-2961. doi: 10.1021/acs.molpharmaceut.2c00307. Epub 2022 Jul 7.
4
Application of the combination of ball-milling and hot-melt extrusion in the development of an amorphous solid dispersion of a poorly water-soluble drug with high melting point.球磨与热熔挤出联用在开发高熔点难溶性药物无定形固体分散体中的应用
RSC Adv. 2019 Jul 17;9(39):22263-22273. doi: 10.1039/c9ra00810a.
5
Industry White Paper: Contemporary Opportunities and Challenges in Characterizing Crystallinity in Amorphous Solid Dispersions.行业白皮书:在无定形固体分散体中描述结晶度的当代机遇和挑战。
J Pharm Sci. 2022 Jun;111(6):1543-1555. doi: 10.1016/j.xphs.2022.01.007. Epub 2022 Jan 15.
6
Revealing the mechanism of morphological variation of amorphous drug nanoparticles formed by aqueous dispersion of ternary solid dispersion.揭示三元固体分散体水分散体形成的无定形药物纳米颗粒形态变化的机制。
Int J Pharm. 2021 Sep 25;607:120984. doi: 10.1016/j.ijpharm.2021.120984. Epub 2021 Aug 11.
7
Ternary solid dispersions: classification and formulation considerations.三元固体分散体:分类和制剂考虑因素。
Drug Dev Ind Pharm. 2021 Jul;47(7):1011-1028. doi: 10.1080/03639045.2021.1908342. Epub 2021 Aug 17.
8
Clarification of the Dissolution Mechanism of an Indomethacin/Saccharin/Polyvinylpyrrolidone Ternary Solid Dispersion by NMR Spectroscopy.通过 NMR 光谱法阐明吲哚美辛/糖精/聚乙烯吡咯烷酮三元固体分散体的溶解机制。
J Pharm Sci. 2020 Dec;109(12):3617-3624. doi: 10.1016/j.xphs.2020.09.009. Epub 2020 Sep 12.
9
Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update.用于递释难溶性药物的共无定形系统:最新进展和更新。
Expert Opin Drug Deliv. 2020 Oct;17(10):1411-1435. doi: 10.1080/17425247.2020.1796631. Epub 2020 Sep 17.
10
Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products.无定形固体分散体:制备、表征、生物利用度机制、稳定性、监管考虑因素和上市产品的更新。
Int J Pharm. 2020 Aug 30;586:119560. doi: 10.1016/j.ijpharm.2020.119560. Epub 2020 Jun 18.